Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

ARS Pharmaceuticals' Long-Term Investments history spans 2 years, with the latest figure at $24.2 million for Q2 2022.

  • For Q2 2022, Long-Term Investments changed N/A year-over-year to $24.2 million; the TTM value through Jun 2022 reached $24.2 million, changed N/A, while the annual FY2021 figure was $64.8 million, N/A changed from the prior year.
  • Long-Term Investments for Q2 2022 was $24.2 million at ARS Pharmaceuticals, down from $44.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $64.8 million in Q4 2021 and bottomed at $24.2 million in Q2 2022.